

REMARKS

Applicants have amended the title to insert "Fused Pyrimidyl."

Applicants have amended the Cross-Reference to Related Applications to indicate that this application's parent has now issued.

Applicants have amended claims 1-3 to insert proper punctuation thus correct inadvertent deletions of punctuation introduced in applicants' last amendment.

Applicants have amended claim 26 to be directed to methods of treating colon ovarian or breast cancer. Support may be found throughout the specification as originally filed.

Applicants have cancelled claims 11, 12, 21, and 22 without prejudice to applicants' ability to file and obtain patent protection for claims directed to this cancelled subject matter in applications claiming priority to the present application under 35 U.S.C. §120.

None of these amendments add any new matter.

The Office Action

Preliminary Matters

The Examiner has requested applicants to amend the title as "the title of the invention is no longer descriptive after restriction." Applicants have amended the title as suggested by the Examiner (i.e., adding "Fused Pyrimidyl" at the beginning of the title). Applicants request that the Examiner approve the amended title.

The Examiner has requested applicants to amend the Cross-reference to related applications to indicate that this application's parent has now issued as a patent. Applicants have updated the Cross-reference accordingly.

35 U.S.C. § 112, Second Paragraph

Claims 11, 12, 21, and 22 stand rejected under 35 U.S.C. § 112, second paragraph as being indefinite. Applicants disagree with the Examiner's rejections. Nevertheless, to expedite prosecution, applicants have cancelled claims 11, 12, 21, and 22.

35 U.S.C. § 112, First Paragraph

Claims 11, 12, 21, 22, and 26 stand rejected under 35 U.S.C. § 112, first paragraph as being indefinite. The Examiner contends that "the specification, while being enabling for treating diabetes, schizophrenia, colon, ovarian, and breast cancer" is not otherwise enabled. Applicants disagree with the Examiner's rejections. Nevertheless, to expedite prosecution, applicants have cancelled claims 11, 12, 21, and 22 thus obviating this aspect of the

prosecution, applicants have cancelled claims 11, 12, 21, and 22 thus obviating this aspect of the rejections. Applicants have amended claim 26 to be directed to only those types of cancers the Examiner contends the applicants have enabled. Accordingly, applicants request that the Examiner withdraw these rejections.

Applicants respectfully request that the Examiner enter the above amendments, consider the foregoing remarks, and allow the pending claims to issue.

Respectfully submitted,



Lisa A. Dixon (Reg. No. 40,995)
Attorney for Applicants
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Telephone: (617)444-6396
Facsimile: (617)444-6483